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Background: Asymptomatic and symptomatic malaria during pregnancy has consequences for both mother and her
offspring. Unfortunately, there is insufficient information on the safety and efficacy of most antimalarials in pregnancy.
Indeed, clinical trials assessing antimalarial treatments systematically exclude pregnancy for fear of teratogenicity and
embryotoxicity. The little available information originates from South East Asia while in sub-Saharan Africa such
information is still limited and needs to be provided.
Design: A Phase 3, non-inferiority, multicentre, randomized, open-label clinical trial on safety and efficacy of 4 ACT when
administered during pregnancy was carried out in 4 African countries: Burkina Faso, Ghana, Malawi and Zambia. This is a
four arm trial using a balanced incomplete block design. Pregnant women diagnosed with malaria are randomised to
receive either amodiaquine-artesunate (AQ-AS), dihydroartemisinin-piperaquine (DHA-PQ), artemether-lumefantrine (AL),
or mefloquine-artesunate (MQAS). They are actively followed up until day 63 post-treatment and then monthly until 4–6
weeks post-delivery. The offspring is visited at the time of the first birthday. The primary endpoint is treatment failure
(PCR adjusted) at day 63 and safety profiles. Secondary endpoints included PCR unadjusted treatment failure up to day
63, gametocyte carriage, Hb changes, placenta malaria, mean birth weight and low birth weight. The primary statistical
analysis will use the combined data from all 4 centres, with adjustment for any centre effects, using an additive model
for the response rates. This will allow the assessment of all 6 possible pair-wise treatment comparisons using all
available data.
Discussion: The strength of this trial is the involvement of several African countries, increasing the generalisability
of the results. In addition, it assesses most ACTs currently available, determining their relative ‘-value-’ compared to
others. The balanced incomplete block design was chosen because using all 4-arms in each site would have increased
complexity in terms of implementation. Excluding HIV-positive pregnant women on antiretroviral drugs may be seen
as a limitation because of the possible interactions between antiretroviral and antimalarial treatments. Nevertheless, the
results of this trial will provide the evidence base for the formulation of malaria treatment policy for pregnant women
in sub-Saharan Africa.
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The risk of malaria is higher in pregnant women than in
the general population. There is insufficient information
on the safety and efficacy of most antimalarial drugs in
pregnancy [1] as they are systematically excluded from
clinical trials for fear of teratogenicity and embryotoxicity
[2]. This has complicated the generation of evidence-
based recommendations for the prevention and treatment
of malaria during pregnancy. Though the experience on
the use of ACTs and their safety and efficacy in pregnancy
is increasing (over 1,000 documented pregnancies, mainly
in South East Asia), such information is still limited in
sub-Saharan Africa [3]. Preclinical data indicate that the
artemisinin derivatives were embryotoxic and potentially
teratogenic in several animal species, without maternal
toxic effects or impaired fertility [2]. More recent studies
confirm these findings. One important aspect is that the
critical window for drug exposure is approximately 10–14
days in the rat and their extrapolation to humans would
indicate a sensitive period of weeks 2–6 of pregnancy [2].
There is increasing experience with the use of artemisinin
derivatives in the second and third trimesters and there
have been no reported adverse effects on the mother or
foetus [4]. Despite limited data the World Health
Organization (WHO) recommends effective artemisinin-
based combination treatments (ACT) in the second and
the third trimester and several African countries are
already implementing it [3].
We propose to assess the efficacy and safety of the most
important ACTs currently available, namely artemether-
lumefantrine (AL), amodiaquine-artesunate (AQ-AS),
mefloquine-artesunate (MQ-AS) and dihydroartemisinin-
piperaquine (DHA-PQ). The choice of ACTs is based on
several criteria, including known treatment efficacy in
children, safety in pivotal phase-3 trials in children and
adults, practicality of the dosing regimen (duration, e.g.
3 vs. 7 days), fixed dose combinations, drug tolerance,
current availability in the population and affordable cost.
The rationale for contemporaneously testing several drug
regimens is to shorten the time of data collection and
determine the relative ‘value’ of each treatment, providing
the basis for an informed choice by malaria control
programmes and policy makers.
Reliable data on the safety and efficacy of ACTs in
pregnant women can be rapidly collected only within the
context of a randomized-controlled trial. The production
of such a large dataset will advance considerably the
knowledge on the treatment of malaria in pregnancy in a
relatively short period of time compared to pregnancy reg-
isters. One of the major issues for this trial is the altered
pharmacokinetic of antimalarial drugs during pregnancy
and the influence on the outcome of treatment. There has
been a recent increase in trials that measure the pharma-
cokinetics of antimalarial drugs in pregnant women [5].Recent information on the pharmacokinetics of both arte-
misinins [6] and partner drugs in the ACT is reassuring as
amodiaquine [7], mefloquine [8] and piperaquine [9] do
not seem to need dose adjustment. Nevertheless, the
pharmacokinetic of lumefantrine (when administered as
co-formulated artemether-lumefantrine) seems altered
in pregnancy [10]. The clinical implications of the PK
findings may not be clear from small rich PK studies alone
and, unless the effects are important, may not be apparent
in a pilot study in one site. Therefore, the proposed study
aims not only at collecting safety and efficacy data on
ACTs in a systematic and standardized manner but also
explanatory variables (pharmacokinetic and in vitro drug
sensitivity) that may help in interpreting the observed
results.
ACTs have been shown to be extremely efficacious in
children [11]. Efficacy is determined by the drug partnering
the artemisinin derivative and, for artesunate–mefloquine,
artemether–lumefantrine, and dihydroartemisinin–pipera-
quine, this usually exceeds 95% [12]. Amodiaquine-
artesunate has proved to be an efficacious combination
(range 90-95%) in areas where 28-day cure rates with
amodiaquine monotherapy exceed 80% [13]. Few data on
pregnant women are available but efficacy should be as
good, if not better, than in children. In all the three areas
where AQAS is assessed, efficacy of AQ monotherapy
exceeds 80%. Therefore, it is expected that all the four
treatments will have an efficacy of about 95%.
Trial objectives and purpose
The main objective of the trial is to determine the safety
and efficacy of 4 ACTs when administered to pregnant
women with P. falciparum infection during the second
and the third trimester, and collect explanatory variables
for therapeutic response. The primary hypothesis is the
clinical equivalence (pair-wise non-inferiority) of the 4
treatment regimens, with clinical equivalence defined as
difference in treatment failure rates (PCR corrected) of
5% or less.
Specific objectives are:
 to compare the efficacy of AL, AQ-AS, MQ-AS and
DHA-PQ in terms of treatment failure by 63 days
after start of treatment with or without genotyping;
Parasite clearance time; Haematological recovery by
14, 28, 42 and 63 days post-treatment and at delivery;
Birth weight measured within 72 hours of delivery;
and prevalence of placenta P. falciparum malaria;
 to describe the safety profile of AL, AQ-AS, MQ-AS
and DHA-PQ in terms of tolerability; incidence of
adverse events until one year post-partum;
 to determine the relation between drug
pharmacokinetics (Day 7 levels of the partner drug)
and response to treatment;
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isolates collected before treatment to several drugs,
including the partner drug tested, and to correlate
their IC50 to treatment response.
Trial design
Study design
This is a non-inferiority, multicentre, randomized, open
label study on 4 antimalarial treatments, namely DHA-
PQ, MQAS, AQAS and AL, assessed in each site using a
“balanced incomplete block design” – with 3 out of 4 arms
used in each site. There are 7 sites in the study distributed
in the four countries, i.e. Burkina Faso (Nanoro and
Nazoanga), Ghana (Effiduase, Ejisu and Juaben), Malawi
(Chikwawa) and Zambia (Nchelenge).
The treatments tested are distributed in a way to allow
a head-to-head comparison and the establishment of
the treatment’s relative value according to a series of
outcomes (Table 1). This approach has the advantage of
testing several treatment options at the same time,
maximizing the use of resources, and is the most likely
to achieve our aim of identifying at least 2 antimalarial
treatments suitable for use in pregnancy and one rescue/
alternative treatment.
The primary analysis is the assessment of therapeutic
equivalence of the 4 treatments (clinical non-inferiority)
with respect to therapeutic success at day 63 and their
safety throughout the follow up, i.e. up to one year after
delivery.
The following procedures are used to ensure an unbiased
assignment of treatment safety and efficacy:
1. The randomization list is generated prior to the
beginning of the study.
2. The interpretation of the PCR reading is blinded or
masked with regard to the treatment allocation of
the patients.
3. An independent Data Safety and Monitoring Board
(DSMB) reviews all safety data.
Primary endpoint
There are two primary end points:Table 1 Treatment arms per country/ site (number
of patients)
West Africa: comparator AQAS
Burkina (870) AL (290) AQAS (290) MQAS (290)
Ghana (870) AQAS (290) MQAS (290) DHA-PQ (290)
Eastern-Southern Africa: comparator AL
Malawi (870) DHA-PQ (290) AL (290) AQAS (290)
Zambia (870) MQAS (290) DHA-PQ (290) AL (290)
AQAS: amodiaquine-artesunate; DHA-PQ: dihydroartemisinin-piperaquine;
AL: artemether-lumefantrine; MQAS: Mefloquine-artesunate.1. Treatment Failure (TF) (PCR adjusted) at day 63
defined according to the WHO criteria [14] as the
sum of early and late treatment failures. Early
Treatment Failure (ETF) could be one of the
following: Development of danger signs or severe
malaria on Day 0, Day 1, Day 2 or Day 3, in the
presence of parasitaemia; Parasite density on Day
2 > Day 0 count, irrespective of axillary temperature;
Presence of parasitaemia on Day 3 with fever
(axillary temperature ≥ 37.5°C); Parasitaemia on Day
3 ≥ 25% of count on Day 0. Late treatment failure
(LTF) is divided in late clinical and late
parasitological failure. Late Clinical Failure (LCF):
Development of danger signs or severe malaria on
any day after Day 3 in the presence of parasitaemia,
without previously meeting any of the criteria of
Early Treatment Failure; Presence of parasitaemia
and fever on any day after Day 3, without having
previously meet the criteria of ETF. Late
Parasitological Failure (LPF): Presence of
parasitaemia on any day from day 7 onwards and
axillary temperature <37.5°C, without previously
meeting any of the criteria of ETF or LCF. The
Adequate Clinical and Parasitological Response
(ACPR) is 1-TF. It is defined as absence of
parasitaemia at the end of the follow up period,
irrespective of axillary temperature without
previously meeting any of the criteria of early and
late treatment failure. In the adjusted estimates,
patients with late asexual parasite reappearance
(with or without fever) are considered ACPR if the
PCR analysis shows a new infection rather than a
recrudescence.
2. Safety profiles including significant changes in
relevant laboratory values. Subjects are monitored for
63 days for possible development of adverse events.
All adverse events are recorded on the specific form
in the electronic CRF. Vital signs, blood chemistry
and haematology are monitored and changes in
relevant laboratory parameters are assessed.
Secondary endpoints
PCR unadjusted treatment failure up to day 63 (TF63U);
Time to treatment failure (PCR adjusted and unadjusted)
during 63 days of active follow-up after treatment; Asexual
parasite clearance time (PCT): Asexual parasite clearance
time is defined as the time (in days) from time of
randomization to 2 consecutive negative blood slides (col-
lected at different days) - the time to the event is taken as
the time to the first negative slide; Gametocytaemia
(prevalence and density) at day 7, 14, 21, 28 and 63 after
treatment; Hb changes day 14, 28, 42 and 63; Acute,
chronic or past infection of the placenta (prevalence);
Mean birth weight and prevalence of low birth weight.
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Haematology Maternal haemoglobin is measured using
Hb301 Hemocue®, Angelholm, Sweden, according to
manufacturer’s instructions.
Peripheral malaria infection Blood samples are collected
by finger prick at specified time points during the trial for
blood slides (thick blood film) and blood spots on filter
paper. Thick blood smears are stained with 3% Giemsa for
30 minutes and read by trained microscopists at each site.
Parasite densities are calculated by counting the number
of asexual parasites per 200 leukocytes (or per 500 leuko-
cytes if the count is <10 asexual parasites/200 leukocytes),
assuming a leukocyte count of 8,000/μl. A blood smear is
considered negative when the examination of 100 high
power fields does not reveal asexual parasites. Each slide
is read separately by two experienced microscopists and
discrepancies resolved by a third reader.
Blood spots on filter paper are used for genotyping
recurrent malaria infections during follow up and com-
pared them with pre-treatment samples. This is done by
characterizing MSP1, MSP2 and GLURP, single-copy
genes in the Plasmodium falciparum genome. For the
three genes, each PCR-amplification product of a differ-
ent size is considered to originate from a different clone
of Plasmodium falciparum, reflecting a different geno-
type. For the samples collected from the same patient at
day 0 and day of recurrent parasitaemia, the length poly-
morphism of MSP1, MSP2 and GLURP are determined,
i.e. the number of bands in each PCR reaction and their
respective size. Results are interpreted as follows:
 Recrudescence: For each marker (MSP1, MSP2 and
GLURP), at least one identical length polymorphism
is found in the sample collected at day 0 and day of
recurrent parasitaemia.
 New infection: For at least one marker, length
polymorphism is different between the sample
collected at day 0 and that at day of recurrent
parasitaemia.
 Indeterminate: Samples that fail to produce a result
due to an inability to amplify DNA at day 0 and/or
day of recurrent parasitaemia.
Placental malaria A 1 cm3 biopsy specimen is obtained
from the maternal-facing side of the placenta as soon as
possible after delivery. Biopsy specimens are preserved
in 10% neutral buffered formalin which are processed
and embedded in paraffin wax by standard techniques.
Pending histological evaluation, all biopsies are kept at
4°C. Paraffin sections 4 mm thick are stained with
haematoxylin-eosin stain.
Placental biopsies are classified according to the fol-
lowing definitions [15]:1. Acute infection (parasite present, malaria pigment
absent)
2. Chronic infection (parasites and malaria pigment
present)
3. Past infection (no parasite but pigment present)
4. No infection (both parasites and malaria pigment
absent)
PK assessment Individual pharmacokinetic studies are
often underpowered for identifying the factors that influ-
ence antimalarial pharmacokinetic parameters, which
may have a major influence on the observed therapeutic
response. Complementing efficacy data with some informa-
tion on the pharmacokinetic properties of the treatment
used allows a better interpretation of the observed recur-
rent infections or true recrudescences/new infections, as
these may be the results of inadequate drug levels because
of altered distribution, poor absorption or metabolism. The
day 7 drug concentration has been shown to be the most
important single measure, in terms of correlation with the
area under the concentration time curve and association
with treatment response, for lumefantrine, piperaquine and
mefloquine [16]. Therefore, a blood sample of 2 ml is col-
lected from all women at day 7 with the aim of measuring
with an appropriate assay the concentration of the partner
drug to the artemisinin derivative. Not all samples will be
analysed; instead a smaller number of samples will be
chosen for the analysis according to the observed thera-
peutic response, i.e. in each arm women having experienced
a true recrudescence will be compared with those having
had a new infection and with those with an adequate
clinical and parasitological response. Analysis of the
blood samples will be carried out within the Malaria in
Pregnancy Consortium.
In-vitro tests This component is carried out at the sites
in Burkina Faso only. The sensitivity of the parasites to
the drugs used is determined by carrying out in vitro tests.
Venous blood samples (5 ml) are collected at day 0 before
treatment from women with a parasite density of at least
4,000/μL. The HRP2 ELISA [17,18] is used to measure the
proliferation of P. falciparum in the presence of lumefan-
trine, monodesethylamodiaquine (active metabolite of
amodiaquine), mefloquine, piperaquine and dihydroarte-
misinin (active metabolite of artemisinin derivatives).
Sample size
The sample size for this study was determined by simu-
lation with the following assumptions and requirements:
(1) study conclusions are determined by two-sided 95%
confidence intervals for difference in response rates (%
of therapeutic success), with decision rule as described
below, (2) all 4 treatments have identical true response
rates of 95%, (3) 95% power for each of the 6 pair-wise
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esis that all treatments are therapeutically equivalent is
required. With these assumptions, approximately 700
patients/treatment arm are needed. If the true response
rate for one of the treatments is lower than 95%, then
power is reduced to 80% (for a true response rate of 94%)
or 50% (for a true response rate of 93%). Allowing for a
20% loss to follow-up, a total of 870 patients are recruited
to each treatment; this is equivalent to 290 patients in
each treatment group in each centre (i.e. a total centre
sample size of 870 patients) – and hence a total study
sample size of 3480 patients. Inclusion of HIV-infected
women is not expected to have a major influence on the
sample size calculation. The percentage of therapeutic
success may be slightly but not dramatically lower in this
subgroup of patients.
For safety, when combined, the trial is able to detect
with 90% power major adverse events occurring at the
frequency of at least 2-3%.
Statistical analysis
A detailed analysis plan is drawn up prior to the
analysis.
1. Baseline comparability: Patients in each treatment
group in each site are described separately with
respect to baseline characteristics. The clinical
importance of any imbalance will be noted, though
statistical tests of significance are not undertaken.
2. Primary analyses: The primary analysis of the study
is the assessment of therapeutic equivalence of the 4
treatments (clinical non-inferiority) with respect to
therapeutic success at day 63 and their safety through-
out the follow-up, i.e. up to one year after delivery.
Efficacy Therapeutic equivalence is assessed using the
pair-wise difference in response rates (percentage of women
with therapeutic success). Assessment of the difference in
true response rates is performed by calculating the two-
sided 95% confidence interval for the difference in response
rates from the observed data, using the following decision
rule:
 if the two-sided 95% confidence interval for
the difference in response rates lies entirely
between −5% and +5%, then therapeutic equivalence
of the two treatments is concluded;
 if the 95% confidence interval for the difference in
response rates includes −5% or +5%, then
therapeutic equivalence cannot be established;
 if the 95% confidence interval for the difference in
response rates lies entirely below −5% or entirely
above 5%, then one treatment is clinically inferior to
the other.The primary analysis uses the combined data from all
4 centres together, with adjustment for any centre effects,
using an additive model for the response rates (i.e. a
generalized linear model with Bernoulli error distribution
and an identity link function). This allows the assessment
of all 6 possible pair-wise treatment comparisons using
all available data. Equivalence will be established using
two-sided confidence intervals. Though 6 treatment com-
parisons will be performed, no adjustment for multiplicity
is needed as the focus of the study is on the individual
pair-wise treatment comparisons. In addition, combined
hypotheses of interest (e.g. all 4 treatments are therapeut-
ically equivalent) require each of the individual hypotheses
to be accepted. Consequently, there is no inflation of the
type I error rate due to multiple testing. However, the
power for combined hypotheses is lower than for the indi-
vidual pair-wise comparisons. Thus, the power calculation
of this study required a high (95%) power for individual
pair-wise treatment comparisons, resulting in an accept-
able (80%) power for the combined hypothesis. For the
efficacy analysis, both an intention-to-treat and a per-
protocol approach are adopted, with the per-protocol
analysis being the primary approach, as recommended
for equivalence studies.
Safety For safety analysis, all non-serious and serious
adverse events (SAE) are grouped according to a pre-
specified side-effect coding system and tabulated. The
number (and percentage) of patients experiencing any
adverse event, any SAE, and any drug-related SAE are com-
pared between treatment groups using Fisher's exact test.
Safety is analyzed using the all-patients-treated approach.
Selection of the patients
All pregnant women in the second and third trimester
(<37 weeks) and attending the antenatal clinic of the
study health facilities are systematically screened for
malaria infection with a rapid diagnostic test; if positive
they are further assessed for eligibility. They are included
if they are at least 15 years old, with a pregnancy of at
least 16 weeks, a P. falciparum monoinfection of any
density, regardless of symptoms, and a Hb concentration
of at least 7 g/dL. Pregnant women with a negative blood
slide are not included in the study and go through the
routine antenatal clinic procedures according to national
policy and receive a dose of sulfadoxine-pyrimethamine
(SP) as intermittent preventive treatment (IPT). Exclusion
criteria include history of allergic reactions to the study
drugs, of known pregnancy complications or bad obstetric
history such as repeated stillbirths or eclampsia, of presence
or history of major illnesses likely to influence pregnancy
outcome, e.g. diabetes mellitus, severe renal or heart
disease, or active tuberculosis, current cotrimoxazole
prophylaxis or ARV treatment. Table 2 provides the full
Table 2 Inclusion and exclusion criteria
Inclusion criteria Patients eligible for inclusion in the trial must fulfil all of the following criteria
Gestation ≥16 weeks and <37 weeks;
P. falciparum monoinfection of any density, with or without symptoms
Hb≥ 7 g/dL;
At least 15 years old;
Residence within the health facility catchment’s area;
Willing to deliver at the health facility;
Willing to adhere to the study requirements (including, in Zambia and Malawi, HIV VCT)
Ability to provide written informed consent; if the woman is minor of age/not emancipated, the consent
must be given by a parent or legal guardian according to national law (however, in this case, the
investigator is responsible to check that the woman herself is also freely willing to take part in the study).
Exclusion criteria Patients who meet any of the following criteria are not eligible for the study
History of allergic reactions to the study drugs;
History of known pregnancy complications or bad obstetric history such as repeated stillbirths or eclampsia;
History or presence of major illnesses likely to influence pregnancy outcome including diabetes mellitus,
severe renal or heart disease, or active tuberculosis;
Current cotrimoxazole prophylaxis or ARV treatment;
Any significant illness at the time of screening that requires hospitalization, including severe malaria;
Intent to move out of the study catchment area before delivery or deliver at relative’s home out of the catchment area.
Prior enrollment in the study or concurrent enrollment in another study.
Unable to take oral medication
Clear evidence of recent (1 week) treatment with antimalarials or antimicrobials with antimalarial activity
(clindamycin; azythromycin; etc.)
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women with any parasite density is justified by the import-
ant adverse outcomes any malaria infection has on the
mother’s and her offspring’s heath. Limiting the inclusion
to women at 16 weeks or more of gestation is justified by
the uncertainty on the safety of ACT when administered
during the first trimester of pregnancy. The gestational
age was confirmed by measuring symphysio-fundal height
and the foetal viability by using an ultra-sonography.
Exclusion criteria are formulated because of possible safety
issues, e.g. history of allergic reactions to the study drugs,
or the need for a clear interpretation of the therapeutic
response, e.g. recent exposure to antimalarial treatments.
Informed consent For the informed consent, all interviews
are conducted in the native language of the patients by a
qualified person identified by the Investigator. Written
information and consent forms in the local language are
provided to the women or Legally Authorized Representa-
tives (LAR) for their review. After the interview, the
patients and, in case they are of minor age/not emanci-
pated, the parents or guardians are asked to confirm their
willingness to participate in the study by signing (or
thumb-printing if illiterate) the consent form.
Each eligible pregnant woman who agrees to give in-
formed consent is assigned a unique study number and
enrolled. Besides malaria infection and parasite density,Hb, total white blood cell count, differential count, total
bilirubin, ALAT and creatinine are measured. In addition,
a blood sample is collected on filter paper for later
genotyping.
Randomization and treatment
Randomisation is carried out according to a pre-established
list comprising blocks of varying size and stratified
according to the number of recruitment points in each site.
Allocation of treatment according to the randomization list
is in sealed envelopes labelled with the patient’s unique
code, guaranteeing concealment until recruitment.
The study treatment is administered during the first 3
study days (days 0–2) by the study doctor or nurse and the
patient kept for one hour in the clinic. If vomiting occurs
within 30 minutes, a full treatment is re-administered, half
a dose if after 30 minutes. In case of persisting vomiting, an
alternative treatment, e.g. quinine, is provided.
Patients follow up
Scheduled visits are at day 3, 7 and then every week until
day 63 post-treatment. However, women are encouraged
to attend the antenatal clinic if they felt ill between sched-
uled visits. At the end of the active follow-up period,
women are asked to attend the antenatal clinic monthly
and at any time they feel unhealthy until delivery. At each
visit, scheduled and unscheduled, the medical history
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signs and symptoms (if any) are collected. A blood sample
for thick and thin blood film and later genotyping to
determine the rate of re-infection is collected and the
body temperature checked. Haematology (Hb, total white
blood cell count, differential count) is measured at day 7,
14, 28 and 63; biochemistry (total bilirubin, ALAT and
creatinine) at day 7 and 14.
If pregnant women recruited during the third trimester
deliver before the end of the 63-day active follow,
scheduled visits continue after delivery until the day 63
is completed. The outcome of pregnancy, including any
congenital abnormality, the birth weight and maternal
Hb are collected as soon as possible after delivery. In
addition, a placenta impression smear and a placenta
biopsy for later histopathological analysis are collected.
Both the mother and the new-born are reassessed twice
after delivery for any adverse event: between 4 and
6 weeks and then after one year (Table 3). Antimalarials
or antibiotics with antimalarial activity (erythromycin or
other macrolides, co-trimoxazole or other sulphonamides,
any tetracycline including doxycycline, and quinolones,
clindamycin) cannot be administered during the active
follow up as it would lead to withdrawal of the patient
from the study.
Patients with treatment failure, including parasitological
failure, are treated with rescue treatment (quinine 10 mg/
kg orally three times a day for 7 days or an anti-malarial
treatment according to the country’s national guidelines)
and their active follow up stopped. Nevertheless, they are
still followed up (safety data) until one year post-delivery.
Safety variables
Safety is closely monitored during the course of the
study in compliance with ICH/GCP guidelines. At each
visit, the investigator ascertains the occurrence of any
adverse events since the previous visit; including those
involving laboratory values which are out of normal
range and are of clinical importance to be considered as
AEs, and the proper AE reporting procedure is followed.
The severity of a clinical adverse event is scored according
to the following scale: mild, moderate, severe and life-
threatening.
Serious Adverse Events (SAEs) are defined as any
untoward medical occurrence that, at any dose of the
medication given, fulfilled the following criteria; death,
life-threatening, requiring hospitalization or prolongation
of hospitalization, resulting in persistent or significant dis-
ability or incapacity, congenital anomaly/ birth defect, or
other situations such as important medical events that
may not be immediately life-threatening or result in death
or hospitalization but may jeopardize the subject or may
require medical or surgical intervention to prevent one of
the other outcomes listed in the above definition. Thereporting investigator assesses the relationship between
investigational product and the occurrence of each AE/
SAE. The relationship of an adverse event to study drug is
assessed according to the following definitions: ‘Definitely
unrelated’, ‘Unlikely’, ‘Possible’, ‘Probable’ and ‘Definitely
related’. The outcome of each AE is assessed according
to the classification as follows – ‘Completely recovered’,
‘Not yet completely recovered’, ‘Deterioration’, ‘Permanent
damage’, ‘Death’, ‘Ongoing’ and ‘Unknown’.
Each SAE has to be reported to the sponsor and to the
concerned ethical bodies in the study countries within
24 working hours since the time the study staff becomes
aware of it, and any reporting delay has to be explained.
All the SAE forms are further sent by the sponsor to the
concerned ethical bodies in Belgium and to the independ-
ent DSMB. Each SAE is followed up until resolution.
Monitoring and quality assurance
Each site is visited at least 3 times during the conduct of
the trial plus a study initiation visit at the start of clinical
activities and a close-out visit after the last patient has
completed the follow up. The monitor will perform the
tasks as described in International Conference on Har-
monisation (ICH)-Good Clinical Practice (GCP) E6,
section 5.18 and will carry out at least 10% source data
verification (SDV). For all sites, the SDV percentage will
be increased by the monitor if the quality of data entry
is found not to be satisfactory.
Case report form and data management
Each patient has her own source document file, according
to a common source document template provided by the
Sponsor, with all the original documents, e.g. laboratory
results. This data is captured into an electronic case report
form (e-CRF) developed in the GCP-compliant software
MACRO (InferMed, UK) for clinical trials. The e-CRF has
in-built consistency checks; data can be entered either
online or offline and then uploaded to be sent to the
central server. The final database is obtained after the
resolution of all queries and then locked for later statistical
analysis done according to a pre-established statistical data
analysis plan.
Study committee
Consortium secretariat The Consortium Secretariat (CS)
acts as a steering committee. It comprises one investigator
from each site and will assess the progress of the trial. The
members of the CS will address policy and operational
issues related to the protocol. The CS has responsibility
for protecting the scientific conduct and integrity of the
trial. Its functions include review of the protocol before
ethical approval; and formulation of recommendation for
any change in the design and operations of the trial during
the course of the trial, when needed.
Table 3 Study procedures/study visit schedule
Day 0 1 2 3 7 14 21 28 35 42 49 56 63 Any other day1 Delivery 4-6 weeks
post-partum
EPI clinics 1 year
post-partum
History (symptoms) X
Informed consent X
Examination (clinical) X X X X X X X X X X X X X X X
Foetal viability X X X X X X X X X X X X
Blood Pressure X X X X X X X X X X X X X X X
Temperature X X X X X X X X X X X X X X X
Blood film X X X X X X X X X X X X X X X
Filter paper PCR X X X X X X X X X X X X2
Adverse events X X X X X X X X X X X X X X X
Concomitant medications X X X X X X X X X X X X X X X X
Hb X X X X X X X
Haematology X X X X X X
Treatment X X X
Blood sample for PK X
Pop PK 3 samples/woman according to a predefined schedule (120 women in 3 sites each)
In vitro test X and time of recurrent infection
Biochemistry X X X X3 X4
Placenta sample X
New born assessment X X
Infant assessment X X
1Spontaneous attendance to the health facility.
2Includes placental blood sample.
3Only ALAT and total bilirubin.
4Only ALAT and total bilirubin, and only if abnormal at Day 28.
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Data Safety and Monitoring Board (DSMB) is composed
by four independent scientists, i.e. a paediatrician, a gynae-
cologist, a statistician and a malariologist. They meet every
three months during recruitment or can be called together
if the necessity arises.
History of amendments to the study protocol Several
amendments (Table 4) have been made to this study proto-
col based on emerging information and were approved
by the relevant ethical committees. Before study start
the ASAQ manufacturer provided information regarding
potential transitory increase of ALAT at day 28 post-
treatment. Therefore, ALAT measurement at day 28 was
introduced. In addition, an overview of the reproductive
toxicity of DHAPQ and mefloquine was made available by
the manufacturer and showed in the animal model pro-
longed length of gestation and dystocic pup expulsion in
animals treated close to delivery. It was therefore, decided
to modified the original inclusion criterion of gesta-
tion ≥16 weeks to gestation ≥16 weeks and <37 weeks.
Another amendment was done on the basis of the
modification of blood piperaquine concentrations by
food intake which could result in a QTc prolongation, arisk factor for serious cardiac arrhythmia. Therefore, the
manufacturer advised to administer DHAPQ tablets with
water only and at least 3 hours apart from meal, mainly
for the second and third administration, and advice the
woman not to eat for the next 3 hours.
Discussion
Pregnant women are one of the high risk groups affected
by the malaria burden and few antimalarials are available
to treat them. This study assesses the efficacy and safety of
four ACTs for the treatment of uncomplicated malaria in
pregnant women in Africa. This is the largest clinical trial
of its kind and will provide the evidence base for the for-
mulation of treatment guidelines for malaria in pregnancy.
Evidence of the interaction between malaria and HIV-1
has already been reported. HIV-1 infected pregnant women
have a higher prevalence of peripheral parasitaemia and
placental malaria [19,20] and their infants experience
higher postnatal mortality when both diseases are present
[4,21]. HIV-1 infected adults have a higher risk of malaria
infection and clinical malaria, the latter increasing with
falling CD4-cell count [22,23]. Therefore, offering adequate
and efficacious antimalarial treatment and prevention is
extremely important for this high risk group. However, little
Table 4 Major amendments
Amendment
version
Basis/rationale of amendment Amendment
Amendment 1 The information provided by the ASAQ manufacturer of some
transitory increase of ALAT at day 28 post-treatment.
ALAT measurement at day 28 was introduced
Amendment 2 The reproductive toxicity of DHAPQ and mefloquine was made
available by the manufacturer and showed in the animal model
prolonged length of gestation and dystocic pup expulsion in
animals treated close to delivery.
Modification of the original inclusion criterion of
gestation ≥16 weeks to gestation ≥16 weeks and <37 weeks
Amendment 3 paragraph on placenta biopsy is added to the ICF
(was omitted by mistake in the previous versions)
Amendment 4 Amendment was done on the basis of the modification of blood
piperaquine concentrations by food intake which could result in a
QTc prolongation, a risk factor for serious cardiac arrhythmia.
• DHA/PQP tablets should be administered with water
only and at least 3 hours apart from meal, mainly for
the second and third administration.
• correction of dosage of DHA/PQP, should be 3 tablets for
3 consecutive days instead of 2 tablets for 3 consecutive days
as erroneously stated in the previous versions of the protocol.
• notification of change in sites in Malawi.
• % of SDV reduced to 10%
Amendment 5 Need for baseline drug plasma concentrations PK sample at day 0 before study drug administration for
the patients participating in the population PK study
Amendment 6 one additional site
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in HIV-infected individuals and much less on the inter-
action between antimalarials and antiretrovirals [24] and
reliable data are urgently needed [3]. HIV-infected individ-
uals have a higher risk of experiencing treatment failure
and this depends on the degree of immune-suppression
[25]. However, no major safety problems related to ACT
treatment in pregnant women have been identified so far.
Considering that most pregnant women recruited in the
study will have an infection with a relatively low parasite
density and that they will be treated with an ACT, it is
expected that the number of treatment failures in this
specific sub-group would be extremely low. They will have
to be treated in any case as the consequences of the
malaria infection on the woman’s health and that of her
offspring are well known.
In the second and third trimester of pregnancy, WHO
recommends the use of ACT known to be effective in
the country/region. Despite this recommendation, it
should be recognised that the available information on
the treatments to be used in this trial is limited. ACT
should not be used in the first trimester of pregnancy,
the time of greatest concern for potential teratogenicity,
and particular care will be taken in excluding women of
this gestational age. DHA-PQ is the least used of the 4
ACTs studied in this trial and it is not among the WHO
recommended ACTs during pregnancy because of insuf-
ficient information [3]. However, DHA-PQ is the first
line treatment in Papua Indonesia, where it is also used
to treat pregnant women with malaria; an observational
study reported significant benefits of DHA-PQ over
quinine-based regimens in reducing recurrent malariaand poor foetal outcome in pregnant women in the
second or third trimester [26]. This trial will increase
significantly the knowledge on the use of DHA-PQ in
African pregnant women.
Trial status
Data collection completed.
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